Ardelyx Company Profile (NASDAQ:ARDX)

About Ardelyx (NASDAQ:ARDX)

Ardelyx logoArdelyx, Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutics focuses on addressing cardiorenal and gastrointestinal (GI) diseases. It operates through the research, development and commercialization of biopharmaceutical products segment. The Company's products line includes cardiorenal portfolio and gastrointestinal portfolio. The Company's cardiorenal portfolio includes two Phase III clinical product candidates, tenapanor in Phase III clinical development for treating hyperphosphatemia in end-stage renal disease (ESRD) patients on dialysis and RDX7675 in Phase III clinical development for treating hyperkalemia in chronic kidney disease (CKD) and heart failure patients. The cardiorenal portfolio includes tenapanor, RDX7675, RDX013 and RDX011. Its gastrointestinal portfolio is led by tenapanor for the treatment of irritable bowel syndrome with constipation (IBS-C). The gastrointestinal portfolio includes tenapanor, RDX8940, RDX011 and RDX023.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ARDX
  • CUSIP: N/A
  • Web: www.ardelyx.com
Capitalization:
  • Market Cap: $253.52 million
  • Outstanding Shares: 47,386,000
Average Prices:
  • 50 Day Moving Avg: $11.04
  • 200 Day Moving Avg: $13.06
  • 52 Week Range: $5.20 - $16.30
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.44
  • P/E Growth: -0.09
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $3.54 per share
  • Price / Book: 1.51
Profitability:
  • EBIDTA: ($116,220,000.00)
  • Return on Equity: -61.31%
  • Return on Assets: -56.54%
Debt:
  • Current Ratio: 13.28%
  • Quick Ratio: 13.28%
Misc:
  • Average Volume: 291,937 shs.
  • Beta: 0.17
  • Short Ratio: 7.2
 

Frequently Asked Questions for Ardelyx (NASDAQ:ARDX)

What is Ardelyx's stock symbol?

Ardelyx trades on the NASDAQ under the ticker symbol "ARDX."

How were Ardelyx's earnings last quarter?

Ardelyx Inc (NASDAQ:ARDX) posted its quarterly earnings data on Friday, May, 5th. The company reported ($0.59) EPS for the quarter, beating analysts' consensus estimates of ($0.65) by $0.06. View Ardelyx's Earnings History.

Where is Ardelyx's stock going? Where will Ardelyx's stock price be in 2017?

5 brokerages have issued 12 month target prices for Ardelyx's shares. Their predictions range from $12.00 to $24.00. On average, they anticipate Ardelyx's stock price to reach $15.60 in the next twelve months. View Analyst Ratings for Ardelyx.

Are investors shorting Ardelyx?

Ardelyx saw a decrease in short interest in April. As of April 28th, there was short interest totalling 991,392 shares, a decrease of 10.7% from the April 13th total of 1,110,477 shares. Based on an average trading volume of 141,447 shares, the short-interest ratio is currently 7.0 days.

Who are some of Ardelyx's key competitors?

Who owns Ardelyx stock?

Ardelyx's stock is owned by many different of retail and institutional investors. Top institutional shareholders include NEA Management Company LLC (0.00%), FMR LLC (0.00%), Perceptive Advisors LLC (3.98%), Vanguard Group Inc. (0.00%), First Manhattan Co. (2.23%) and RA Capital Management LLC (1.75%). Company insiders that own Ardelyx stock include David P Rosenbaum, Elizabeth A Grammer, Enterprise Associates 12 New, Gordon Ringold, Jeffrey W Jacobs, Jeremy S Caldwell, Michael Raab, Nea 15 Gp, Llc and Peter G Schultz. View Institutional Ownership Trends for Ardelyx.

Who sold Ardelyx stock? Who is selling Ardelyx stock?

Ardelyx's stock was sold by a variety of institutional investors in the last quarter, including RA Capital Management LLC, FMR LLC, First Manhattan Co., JPMorgan Chase & Co., Credit Suisse AG, Morgan Stanley, ProShare Advisors LLC and TD Asset Management Inc.. Company insiders that have sold Ardelyx stock in the last year include David P Rosenbaum, Elizabeth A Grammer, Jeffrey W Jacobs and Jeremy S Caldwell. View Insider Buying and Selling for Ardelyx.

Who bought Ardelyx stock? Who is buying Ardelyx stock?

Ardelyx's stock was purchased by a variety of institutional investors in the last quarter, including MARSHALL WACE ASIA Ltd, Marshall Wace North America L.P., Teachers Advisors LLC, Sphera Funds Management LTD., Driehaus Capital Management LLC, Victory Capital Management Inc., Emory University and Perceptive Advisors LLC. Company insiders that have bought Ardelyx stock in the last two years include Enterprise Associates 12 New, Gordon Ringold, Nea 15 Gp, Llc and Peter G Schultz. View Insider Buying and Selling for Ardelyx.

How do I buy Ardelyx stock?

Shares of Ardelyx can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Ardelyx stock cost?

One share of Ardelyx stock can currently be purchased for approximately $5.35.

Analyst Ratings

Consensus Ratings for Ardelyx (NASDAQ:ARDX) (?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $15.60 (191.59% upside)

Analysts' Ratings History for Ardelyx (NASDAQ:ARDX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/23/2017BTIG ResearchLower Price TargetBuy$18.00 -> $12.00HighView Rating Details
5/19/2017Cantor FitzgeraldReiterated RatingOverweight$19.00 -> $12.00LowView Rating Details
5/15/2017Citigroup IncReiterated RatingBuy$17.00 -> $12.00MediumView Rating Details
2/15/2017WedbushReiterated RatingOutperform$24.00N/AView Rating Details
11/20/2016Leerink SwannSet Price TargetBuy$18.00N/AView Rating Details
3/31/2016Ladenburg Thalmann Financial ServicesInitiated CoverageBuy$21.00N/AView Rating Details
3/9/2016JPMorgan Chase & Co.Lower Price TargetMarket Outperform$26.00 -> $21.00N/AView Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$26.00 -> $21.00N/AView Rating Details
(Data available from 5/25/2015 forward)

Earnings

Earnings History for Ardelyx (NASDAQ:ARDX)
Earnings by Quarter for Ardelyx (NASDAQ:ARDX)
Earnings History by Quarter for Ardelyx (NASDAQ:ARDX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/5/2017Q1 2017($0.65)($0.59)ViewN/AView Earnings Details
2/17/2017Q4 2016($0.66)($0.66)ViewN/AView Earnings Details
11/7/2016Q316($0.74)($0.65)ViewListenView Earnings Details
8/8/2016Q216($0.75)($0.83)ViewN/AView Earnings Details
5/9/2016Q116($0.66)($0.70)ViewN/AView Earnings Details
3/4/2016Q4($0.82)($0.65)ViewN/AView Earnings Details
11/12/2015Q315($0.48)($0.70)ViewListenView Earnings Details
8/12/2015Q215$0.09$0.42$25.87 million$17.70 millionViewListenView Earnings Details
5/12/2015Q1($0.02)($0.19)$9.65 million$5.88 millionViewN/AView Earnings Details
2/25/2015Q4 2014($0.06)($0.21)$8.15 million$6.34 millionViewListenView Earnings Details
8/7/2014Q2 2014$1.83$0.44$8.10 million$9.14 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Ardelyx (NASDAQ:ARDX)
2017 EPS Consensus Estimate: ($2.57)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.65)($0.65)($0.65)
Q2 20171($0.63)($0.63)($0.63)
Q3 20171($0.66)($0.66)($0.66)
Q4 20172($0.70)($0.56)($0.63)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Ardelyx (NASDAQ:ARDX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Ardelyx (NASDAQ:ARDX)
Insider Ownership Percentage: 15.46%
Institutional Ownership Percentage: 81.65%
Insider Trades by Quarter for Ardelyx (NASDAQ:ARDX)
Institutional Ownership by Quarter for Ardelyx (NASDAQ:ARDX)
Insider Trades by Quarter for Ardelyx (NASDAQ:ARDX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/18/2017David P. RosenbaumInsiderSell2,051$11.98$24,570.98View SEC Filing  
3/3/2017Jeremy S. CaldwellEVPSell1,026$14.14$14,507.64View SEC Filing  
12/16/2016David P RosenbaumSVPSell900$14.48$13,032.00View SEC Filing  
10/11/2016Jeffrey W. JacobsSVPSell6,000$15.00$90,000.00View SEC Filing  
9/23/2016Elizabeth A GrammerSVPSell5,000$12.00$60,000.00View SEC Filing  
9/19/2016Elizabeth A. GrammerSVPSell6,859$11.21$76,889.39View SEC Filing  
7/18/2016Nea 15 Gp, LlcMajor ShareholderBuy1,527,301$8.73$13,333,337.73View SEC Filing  
3/21/2016Gordon RingoldDirectorBuy15,000$7.77$116,550.00View SEC Filing  
1/13/2016Nea 15 Gp, LlcMajor ShareholderBuy1,000,000$10.00$10,000,000.00View SEC Filing  
11/27/2015Jeffrey W. JacobsSVPSell2,000$20.00$40,000.00View SEC Filing  
10/8/2015Jeffrey W. JacobsSVPSell2,000$19.88$39,760.00View SEC Filing  
9/22/2015David P. RosenbaumSVPSell1,400$22.05$30,870.00View SEC Filing  
9/15/2015David P RosenbaumSVPSell2,540$22.01$55,905.40View SEC Filing  
9/10/2015Jeffrey W. JacobsSVPSell2,000$20.59$41,180.00View SEC Filing  
9/8/2015Michael RaabCEOSell9,785$20.29$198,537.65View SEC Filing  
9/3/2015David P RosenbaumSVPSell2,537$18.78$47,644.86View SEC Filing  
7/22/2015Elizabeth A GrammerVPSell2,500$18.00$45,000.00View SEC Filing  
7/15/2015Elizabeth A GrammerVPSell10,000$17.12$171,200.00View SEC Filing  
6/10/2015Gordon RingoldDirectorBuy10,000$15.19$151,900.00View SEC Filing  
6/5/2015Enterprise Associates 12 NewMajor ShareholderBuy1,869,159$10.70$20,000,001.30View SEC Filing  
6/5/2015Peter G SchultzDirectorBuy46,729$10.70$500,000.30View SEC Filing  
5/4/2015Mark KaufmannCFOSell9,083$10.81$98,187.23View SEC Filing  
4/6/2015Mark KaufmannCFOSell7,681$12.80$98,316.80View SEC Filing  
3/2/2015Elizabeth A GrammerVPSell1,737$15.81$27,461.97View SEC Filing  
2/4/2015Jeffrey W JacobsVPSell8,888$16.28$144,696.64View SEC Filing  
1/8/2015Ventures Vii Lp CmeaMajor ShareholderSell300,000$24.25$7,275,000.00View SEC Filing  
12/26/2014Scott D SandellMajor ShareholderSell1,972$21.28$41,964.16View SEC Filing  
6/24/2014Ventures Vii Lp CmeaMajor ShareholderBuy316,826$14.00$4,435,564.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Ardelyx (NASDAQ:ARDX)
Latest Headlines for Ardelyx (NASDAQ:ARDX)
Source:
DateHeadline
americanbankingnews.com logoZacks Investment Research Upgrades Ardelyx Inc (ARDX) to Buy
www.americanbankingnews.com - May 23 at 4:24 PM
americanbankingnews.com logoArdelyx Inc (ARDX) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - May 23 at 8:36 AM
americanbankingnews.com logoArdelyx Inc (ARDX) Forecasted to Post FY2017 Earnings of ($2.84) Per Share
www.americanbankingnews.com - May 22 at 7:22 AM
americanbankingnews.com logo-$0.63 Earnings Per Share Expected for Ardelyx Inc (ARDX) This Quarter
www.americanbankingnews.com - May 19 at 1:20 PM
americanbankingnews.com logoArdelyx Inc (ARDX) Earns "Overweight" Rating from Cantor Fitzgerald
www.americanbankingnews.com - May 19 at 10:52 AM
americanbankingnews.com logoArdelyx Inc (ARDX) Given "Buy" Rating at Citigroup Inc
www.americanbankingnews.com - May 15 at 3:50 PM
americanbankingnews.com logoShort Interest in Ardelyx Inc (ARDX) Decreases By 10.7%
www.americanbankingnews.com - May 15 at 8:48 AM
nasdaq.com logoAZN's PACIFIC Proves To Have Depth, ARDX Abuzz, No Flashy Data From ALLSTAR
www.nasdaq.com - May 14 at 3:42 PM
streetinsider.com logoArdelyx (ARDX) Phase 3 T3MPO-1 Trial of Tenapanor in Patients with IBS-C Meets Primary Endpoint
www.streetinsider.com - May 12 at 9:13 PM
finance.yahoo.com logoArdelyx Reports Successful Phase 3 T3MPO-1 Trial of Tenapanor in Patients with IBS-C
finance.yahoo.com - May 12 at 4:11 PM
americanbankingnews.com logoArdelyx Inc (ARDX) Raised to Hold at Zacks Investment Research
www.americanbankingnews.com - May 11 at 10:52 PM
americanbankingnews.com logoWedbush Analysts Boost Earnings Estimates for Ardelyx Inc (ARDX)
www.americanbankingnews.com - May 11 at 9:16 AM
americanbankingnews.com logoArdelyx Inc (ARDX) Announces Quarterly Earnings Results
www.americanbankingnews.com - May 8 at 3:36 PM
finance.yahoo.com logoArdelyx Reports First Quarter 2017 Operating Results and Highlights Recent Progress
finance.yahoo.com - May 5 at 3:38 PM
finance.yahoo.com logoArdelyx reports 1Q loss
finance.yahoo.com - May 5 at 3:38 PM
americanbankingnews.com logoSomewhat Critical Press Coverage Somewhat Likely to Impact Ardelyx (ARDX) Share Price
www.americanbankingnews.com - May 2 at 5:28 PM
americanbankingnews.com logo Analysts Anticipate Ardelyx Inc (ARDX) to Announce -$0.61 Earnings Per Share
www.americanbankingnews.com - April 28 at 11:36 AM
americanbankingnews.com logoArdelyx (ARDX) Getting Favorable News Coverage, Report Shows
www.americanbankingnews.com - April 28 at 10:24 AM
americanbankingnews.com logoArdelyx Inc (ARDX) Downgraded by Zacks Investment Research
www.americanbankingnews.com - April 25 at 6:16 PM
americanbankingnews.com logoSomewhat Negative Media Coverage Somewhat Likely to Affect Ardelyx (ARDX) Share Price
www.americanbankingnews.com - April 25 at 1:08 PM
americanbankingnews.com logoArdelyx (ARDX) Receives Daily News Impact Rating of -0.12
www.americanbankingnews.com - April 22 at 10:22 AM
americanbankingnews.com logoArdelyx Inc (ARDX) Insider David P. Rosenbaum Sells 2,051 Shares
www.americanbankingnews.com - April 21 at 9:30 PM
finance.yahoo.com logoArdelyx To Present at Upcoming Spring Medical Meetings
finance.yahoo.com - April 18 at 9:11 AM
americanbankingnews.com logoArdelyx (ARDX) Receives Media Sentiment Rating of 0.56
www.americanbankingnews.com - April 13 at 8:26 AM
americanbankingnews.com logo Analysts Anticipate Ardelyx Inc (ARDX) Will Post Quarterly Sales of $0.00
www.americanbankingnews.com - April 9 at 9:44 AM
americanbankingnews.com logo-$0.61 EPS Expected for Ardelyx Inc (ARDX) This Quarter
www.americanbankingnews.com - April 7 at 5:35 PM
biz.yahoo.com logoARDELYX, INC. Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - March 9 at 9:13 PM
finance.yahoo.com logoArdelyx Announces Presentation at Cowen and Company 37th Annual Healthcare Conference
finance.yahoo.com - February 28 at 10:14 AM
finance.yahoo.com logoWedbush Has A New Best Idea For 2017: Ardelyx
finance.yahoo.com - February 23 at 3:37 PM
finance.yahoo.com logoARDELYX, INC. Financials
finance.yahoo.com - February 23 at 3:37 PM
finance.yahoo.com logoArdelyx reports 4Q loss - Yahoo Finance - Yahoo Finance
finance.yahoo.com - February 18 at 3:34 PM
us.rd.yahoo.com logoBlog Coverage Ardelyx Reports Positive Data for the Treatment for Hyperphosphatemia in Patients with End-Stage Renal disease
us.rd.yahoo.com - February 17 at 6:32 PM
us.rd.yahoo.com logoArdelyx Reports Clinical Progress and Fourth Quarter and Full Year 2016 Financial Results
us.rd.yahoo.com - February 17 at 6:32 PM
biz.yahoo.com logoARDELYX, INC. Files SEC form 10-K, Annual Report
biz.yahoo.com - February 17 at 6:32 PM
us.rd.yahoo.com logoArdelyx Announces Successful Phase 3 Trial of Tenapanor for Hyperphosphatemia in Patients with End-Stage Renal Disease
us.rd.yahoo.com - February 16 at 8:41 PM
us.rd.yahoo.com logoArdelyx Announces Successful Phase 3 Trial of Tenapanor for Hyperphosphatemia in Patients with End-Stage Renal Disease
us.rd.yahoo.com - February 16 at 8:41 PM
us.rd.yahoo.com logo6:31 am Ardelyx reports its Phase 3 trial evaluating tenapanor as a treatment for hyperphosphatemia in patients with end-stage renal disease who are on dialysis met its primary endpoint and was generally well-tolerated
us.rd.yahoo.com - February 16 at 8:41 PM
us.rd.yahoo.com logo6:31 am Ardelyx reports its Phase 3 trial evaluating tenapanor as a treatment for hyperphosphatemia in patients with end-stage renal disease who are on dialysis met its primary endpoint and was generally well-tolerated
us.rd.yahoo.com - February 16 at 8:41 PM
rttnews.com logoARDX Kidney Drug Passes Phase 3 Study, EDIT Up On CRISPR News, FDA Nod For VRX - RTT News
www.rttnews.com - February 16 at 8:32 AM
investopedia.com logoArdelyx Says Tenapanor Did Well In Study (ARDX) - Investopedia
www.investopedia.com - February 16 at 8:32 AM
biz.yahoo.com logoARDELYX, INC. Files SEC form 8-K, Other Events
biz.yahoo.com - February 16 at 8:32 AM
thestreet.com logoBiotech Premarket Movers: Ardelyx, Acorda Therapeutics, Medicines Co.
www.thestreet.com - February 16 at 8:32 AM
investopedia.com logoArdelyx Says Tenapanor Did Well In Phase 3 Study
www.investopedia.com - February 16 at 8:32 AM

Social

Chart

Ardelyx (ARDX) Chart for Thursday, May, 25, 2017

This page was last updated on 5/25/2017 by MarketBeat.com Staff